度普利尤单抗治疗青少年中重度特应性皮炎:3期随机临床试验
该3期随机双盲试验纳入251例局部治疗控制不佳或不适宜局部治疗的中重度青少年特应性皮炎患者,评估度普利尤单抗单药治疗16周的疗效与安全性。结果显示,每2周和每4周方案均显著提高EASI-75应答率(41.5%和38.1% vs 安慰剂8.2%),且安全性可接受。
要点
- 度普利尤单抗每2周或每4周方案均显著改善青少年中重度AD的EASI-75应答。
- 每2周方案疗效总体上优于每4周方案。
- 常见不良事件为结膜炎和注射部位反应,非疱疹性皮肤感染发生率低于安慰剂。
核心结论
- 度普利尤单抗显著改善青少年中重度AD的体征、症状和生活质量,安全性可接受。
- 青少年与成人中度普利尤单抗的安慰剂校正疗效和安全性相似。
研究设计与样本
- 随机、双盲、平行组、3期临床试验,在美国和加拿大45个中心开展,2017年3月21日至2018年6月5日。
- 共纳入251例局部治疗控制不佳或不适宜局部治疗的中重度AD青少年患者。
- 患者按1:1:1随机接受16周治疗:度普利尤单抗200 mg每2周(基线体重<60 kg,n=43)、300 mg每2周(基线体重≥60 kg,n=39)、300 mg每4周(n=84)或安慰剂(n=85)。
- 主要终点为第16周EASI-75应答率和IGA 0或1的比例。
主要发现
- 第16周EASI-75应答率:每2周组41.5%,每4周组38.1%,安慰剂组8.2%。
- 与安慰剂的差异:每2周组33.2%(95% CI 21.1%-45.4%),每4周组29.9%(95% CI 17.9%-41.8%),P < .001。
- 每2周方案疗效总体上优于每4周方案。
- 结膜炎发生率:每2周组9.8%,每4周组10.8%,安慰剂组4.7%。
- 注射部位反应发生率:每2周组8.5%,每4周组6.0%,安慰剂组3.5%;非疱疹性皮肤感染发生率:每2周组9.8%,每4周组9.6%,安慰剂组18.8%。
关键数值与推荐
- EASI-75定义为EASI评分较基线改善≥75%,EASI评分范围0-72分,分数越高表示越严重。
- IGA 0或1定义为5分制量表评分为0或1,量表范围0-4分,分数越高表示越严重。
- 共250例患者有合并过敏性疾病数据,其中哮喘134例(53.6%)、食物过敏60.8%、过敏性鼻炎65.6%。
- 240例患者(95.6%)完成研究。
临床怎么用
- 度普利尤单抗可用于局部治疗控制不佳或不适宜局部治疗的中重度青少年AD患者。
- 每2周方案疗效优于每4周方案,选择方案时需结合体重和临床情况。
- 治疗期间需关注结膜炎和注射部位反应,非疱疹性皮肤感染发生率较低。
局限性
- 研究仅在美国和加拿大开展,可能限制其普遍性。
- 随访时间为16周,缺乏长期疗效和安全性数据。
- 每2周组样本量较小(200 mg组43例,300 mg组39例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Adolescents with atopic dermatitis (AD) have high disease burden negatively affecting quality of life, with limited treatment options. The efficacy and safety of dupilumab, a monoclonal antibody, approved for treatment in adolescent patients with inadequately controlled AD, remain unknown in this patient population. OBJECTIVE: To assess the efficacy and safety of dupilumab monotherapy in adolescents with moderate to severe inadequately controlled AD. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, parallel-group, phase 3 clinical trial was conducted at 45 US and Canadian centers between March 21, 2017, and June 5, 2018. A total of 251 adolescents with moderate to severe AD inadequately controlled by topical medications or for whom topical therapy was inadvisable were included. INTERVENTIONS: Patients were randomized (1:1:1; interactive-response system; stratified by severity and body weight) to 16-week treatment with dupilumab, 200 mg (n = 43; baseline weight <60 kg), or dupilumab, 300 mg (n = 39; baseline weight ≥60 kg), every 2 weeks; dupilumab, 300 mg, every 4 weeks (n = 84); or placebo (n = 85). MAIN OUTCOMES AND MEASURES: Proportion of patients with 75% or more improvement from baseline in Eczema Area and Severity Index (EASI-75) (scores range from 0 to 72, with higher scores indicating greater severity) and Investigator's Global Assessment (IGA) 0 or 1 on a 5-point scale (scores range from 0 to 4, with higher scores indicating greater severity) at week 16. RESULTS: A total of 251 patients were randomized (mean [SD] age, 14.5 [1.7] years; 148 [59.0%] male). Of 250 patients with data available on concurrent allergic conditions, most had comorbid type 2 diseases (asthma, 134 [53.6%]; food allergies, 60.8%; allergic rhinitis, 65.6%). A total of 240 patients (95.6%) completed the study. Dupilumab achieved both coprimary end points at week 16. The proportion of patients with EASI-75 improvement from baseline increased (every 2 weeks, 41.5%; every 4 weeks, 38.1%; placebo, 8.2%) with differences vs placebo of 33.2% (95% CI, 21.1%-45.4%) for every 2 weeks and 29.9% (95% CI, 17.9%-41.8%) for every 4 weeks (P < .001). Efficacy of the every-2-week regimen was generally superior to the every-4-week regimen. Patients in the dupilumab arms had higher percentage values of conjunctivitis (every 2 weeks, 9.8%; every 4 weeks, 10.8%; placebo, 4.7%) and injection-site reactions (every 2 weeks, 8.5%; every 4 weeks, 6.0%; placebo, 3.5%), and lower nonherpetic skin infections (every 2 weeks, 9.8%; every 4 weeks, 9.6%; placebo, 18.8%). CONCLUSIONS AND RELEVANCE: In this study, dupilumab significantly improved AD signs, symptoms, and quality of life in adolescents with moderate to severe AD, with an acceptable safety profile. Placebo-corrected efficacy and safety of dupilumab were similar in adolescents and adults. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03054428.
引用
- Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020. PMID: 31693077. doi:10.1001/jamadermatol.2019.3336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。